Archive | Publications

Bempegaldesleukin Plus Nivolumab Granted Breakthrough Designation in Melanoma by the FDA

The combination of bempegaldesleukin (NKTR-214) and nivolumab (Opdivo) was granted a breakthrough therapy designation by the FDA for the treatment of patients with previously untreated unresectable or metastatic melanoma.

Read the full story

Posted in Melanoma News, Regulatory, Publications

FDA Approval in TGCT, Breakthrough Designation in Melanoma, and More

An FDA approval in tenosynovial giant cell tumor, a breakthrough therapy designation in melanoma, and encouraging findings in trials in bladder cancer, lung cancer, and a cell-free DNA assay.

Read the full story

Posted in Melanoma News, Regulatory, Publications

Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study

In a prospective cohort of women in France, researchers assessed melanoma risk in relation to menopausal hormone therapy (MHT) use.

Read the full story

Posted in Melanoma News, Publications, Scientific Publications

Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review

In melanoma patients, the efficacy and safety of two treatment regimens were compared: BRAF inhibition plus MEK inhibition combination therapy vs BRAF inhibition monotherapy, via this meta-analysis.

Read the full story

Posted in Melanoma News, Publications, Scientific Publications